Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue

Because the permeability of the blood‐brain barrier to lipid microspheres (LMs) has not hitherto been demonstrated, blood‐brain‐barrier permeability to LM containing the prostaglandin I2 analogue clinprost has been evaluated for an in‐vitro system of primary cultured monolayers of bovine brain capil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacy and pharmacology 1996-10, Vol.48 (10), p.1016-1022
Hauptverfasser: Minagawa, Toshiya, Sakanaka, Kohji, Inaba, Shin-Ichi, Sai, Yoshimichi, Tamai, Ikumi, Suwa, Toshio, Tsuji, Akira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1022
container_issue 10
container_start_page 1016
container_title Journal of pharmacy and pharmacology
container_volume 48
creator Minagawa, Toshiya
Sakanaka, Kohji
Inaba, Shin-Ichi
Sai, Yoshimichi
Tamai, Ikumi
Suwa, Toshio
Tsuji, Akira
description Because the permeability of the blood‐brain barrier to lipid microspheres (LMs) has not hitherto been demonstrated, blood‐brain‐barrier permeability to LM containing the prostaglandin I2 analogue clinprost has been evaluated for an in‐vitro system of primary cultured monolayers of bovine brain capillary endothelial cells (BCECs), by a capillary depletion study in rats and by an in‐situ brain perfusion study in normal and 4‐vessel‐occluded fore brain ischaemic rats. Although energy‐dependency was not observed in [3H]clinprost uptake by BCECs, in accordance with results for simple diffusional transport, uptake of [3H]clinprost contained in lipid microspheres (denoted [3H]clinprost(LM)) was significantly inhibited by the endocytosis inhibitor, dansylcadaverine. The transport of LM into BCECs by endocytosis was also confirmed by fluorescence microscopy and flow‐cytometric analysis using LM labelled with a fluorescent probe, 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethylindocarbocyanine perchlorate (DiI). The absolute uptake of DiI(LM) by BCECs, measured by HPLC, was, however, almost 1/10 that of [3H]clinprost(LM), results which suggest the superiority of simple diffusion of clinprost over endocytosis of its LM form in the uptake of clinprost(LM) by BCECs. In the capillary‐depletion study with rat‐brain‐perfused [3H]clinprost(LM) from the internal carotid artery, the parenchyma apparent distribution volume was about 45 times larger than that of the capillary, showing that [3H]clinprost(LM) was transported through the blood‐brain barrier into the brain. The permeability coefficients of [3H]clinprost and [3H]clinprost(LM) determined by in‐situ brain perfusion in normal rats were considerably higher than those of the active metabolite [3H]isocarbacyclin and its LM form. In addition, the Blood‐brain‐barrier permeabilities to [3H]clinprost, [3H]isocarbacyclin and their LM forms in ischaemic rats were almost identical to those in normal rats. It was concluded that clinprost(LM) was transported through the blood‐brain barrier by endocytosis of LM, simple diffusion of clinprost released from LM, and transport of isocarbacyclin generated by hydrolysis of clinprost. The blood‐brain‐barrier permeability of clinprost(LM) is not reduced in ischaemic conditions, because the simple diffusion of clinprost released from LM contributed mainly to clinprost(LM) transport.
doi_str_mv 10.1111/j.2042-7158.1996.tb05893.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78604408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78604408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4053-e30eae5f7cb52e7bcbef656c82aa68e363462874fa545a1d78c99444c125637a3</originalsourceid><addsrcrecordid>eNqVkF1v0zAYhS0EGmXwE5AshHZFguPPhKtt1b5Qu_WiiEvLcd4UlzTJ7FTr_j2OGvUe3_iVznmPjx-EvmQkzeL5vk0p4TRRmcjTrChkOpRE5AVLD2_Q7CS9RTNCKE2YUOw9-hDClhCipJRn6CwvBBOEzhBcN11XJaU3rk1K470Dj9fetKHv_IC7Gi9c7yq8dNZ3of8DHgKed-0Q_a7d4Hnj2j4qwzds8GoczKYxbeVa_EDxVWuabrOHj-hdbZoAn6b7HP26vVnP75PF093D_GqRWE4ES4ARMCBqZUtBQZW2hFoKaXNqjMyBScYlzRWvjeDCZJXKbVFwzm1GhWTKsHN0ccyNlZ73EAa9c8FCExtBtw9a5ZJwTvJo_HE0jr8KHmrde7cz_lVnRI-M9VaPIPUIUo-M9cRYH-Ly5-mVfbmD6rQ6QY3610k3wZqmjjStCycb5WPnLNouj7YX18DrfxTQP1f3q3GMEckxwoUBDqcI4_9qqZgS-vfjnV5er2-Xslhoyv4BOOio-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78604408</pqid></control><display><type>article</type><title>Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Minagawa, Toshiya ; Sakanaka, Kohji ; Inaba, Shin-Ichi ; Sai, Yoshimichi ; Tamai, Ikumi ; Suwa, Toshio ; Tsuji, Akira</creator><creatorcontrib>Minagawa, Toshiya ; Sakanaka, Kohji ; Inaba, Shin-Ichi ; Sai, Yoshimichi ; Tamai, Ikumi ; Suwa, Toshio ; Tsuji, Akira</creatorcontrib><description>Because the permeability of the blood‐brain barrier to lipid microspheres (LMs) has not hitherto been demonstrated, blood‐brain‐barrier permeability to LM containing the prostaglandin I2 analogue clinprost has been evaluated for an in‐vitro system of primary cultured monolayers of bovine brain capillary endothelial cells (BCECs), by a capillary depletion study in rats and by an in‐situ brain perfusion study in normal and 4‐vessel‐occluded fore brain ischaemic rats. Although energy‐dependency was not observed in [3H]clinprost uptake by BCECs, in accordance with results for simple diffusional transport, uptake of [3H]clinprost contained in lipid microspheres (denoted [3H]clinprost(LM)) was significantly inhibited by the endocytosis inhibitor, dansylcadaverine. The transport of LM into BCECs by endocytosis was also confirmed by fluorescence microscopy and flow‐cytometric analysis using LM labelled with a fluorescent probe, 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethylindocarbocyanine perchlorate (DiI). The absolute uptake of DiI(LM) by BCECs, measured by HPLC, was, however, almost 1/10 that of [3H]clinprost(LM), results which suggest the superiority of simple diffusion of clinprost over endocytosis of its LM form in the uptake of clinprost(LM) by BCECs. In the capillary‐depletion study with rat‐brain‐perfused [3H]clinprost(LM) from the internal carotid artery, the parenchyma apparent distribution volume was about 45 times larger than that of the capillary, showing that [3H]clinprost(LM) was transported through the blood‐brain barrier into the brain. The permeability coefficients of [3H]clinprost and [3H]clinprost(LM) determined by in‐situ brain perfusion in normal rats were considerably higher than those of the active metabolite [3H]isocarbacyclin and its LM form. In addition, the Blood‐brain‐barrier permeabilities to [3H]clinprost, [3H]isocarbacyclin and their LM forms in ischaemic rats were almost identical to those in normal rats. It was concluded that clinprost(LM) was transported through the blood‐brain barrier by endocytosis of LM, simple diffusion of clinprost released from LM, and transport of isocarbacyclin generated by hydrolysis of clinprost. The blood‐brain‐barrier permeability of clinprost(LM) is not reduced in ischaemic conditions, because the simple diffusion of clinprost released from LM contributed mainly to clinprost(LM) transport.</description><identifier>ISSN: 0022-3573</identifier><identifier>EISSN: 2042-7158</identifier><identifier>DOI: 10.1111/j.2042-7158.1996.tb05893.x</identifier><identifier>PMID: 8953502</identifier><identifier>CODEN: JPPMAB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Biological and medical sciences ; Blood-Brain Barrier ; Brain Ischemia - metabolism ; Cattle ; Cells, Cultured ; Drug Carriers ; Epoprostenol - administration &amp; dosage ; Epoprostenol - analogs &amp; derivatives ; Epoprostenol - pharmacokinetics ; General pharmacology ; Lipids ; Medical sciences ; Microspheres ; Permeability ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Prostaglandins, Synthetic - administration &amp; dosage ; Prostaglandins, Synthetic - pharmacokinetics ; Rats ; Rats, Inbred F344</subject><ispartof>Journal of pharmacy and pharmacology, 1996-10, Vol.48 (10), p.1016-1022</ispartof><rights>1996 Royal Pharmaceutical Society of Great Britain</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4053-e30eae5f7cb52e7bcbef656c82aa68e363462874fa545a1d78c99444c125637a3</citedby><cites>FETCH-LOGICAL-c4053-e30eae5f7cb52e7bcbef656c82aa68e363462874fa545a1d78c99444c125637a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2494441$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8953502$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minagawa, Toshiya</creatorcontrib><creatorcontrib>Sakanaka, Kohji</creatorcontrib><creatorcontrib>Inaba, Shin-Ichi</creatorcontrib><creatorcontrib>Sai, Yoshimichi</creatorcontrib><creatorcontrib>Tamai, Ikumi</creatorcontrib><creatorcontrib>Suwa, Toshio</creatorcontrib><creatorcontrib>Tsuji, Akira</creatorcontrib><title>Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue</title><title>Journal of pharmacy and pharmacology</title><addtitle>J Pharm Pharmacol</addtitle><description>Because the permeability of the blood‐brain barrier to lipid microspheres (LMs) has not hitherto been demonstrated, blood‐brain‐barrier permeability to LM containing the prostaglandin I2 analogue clinprost has been evaluated for an in‐vitro system of primary cultured monolayers of bovine brain capillary endothelial cells (BCECs), by a capillary depletion study in rats and by an in‐situ brain perfusion study in normal and 4‐vessel‐occluded fore brain ischaemic rats. Although energy‐dependency was not observed in [3H]clinprost uptake by BCECs, in accordance with results for simple diffusional transport, uptake of [3H]clinprost contained in lipid microspheres (denoted [3H]clinprost(LM)) was significantly inhibited by the endocytosis inhibitor, dansylcadaverine. The transport of LM into BCECs by endocytosis was also confirmed by fluorescence microscopy and flow‐cytometric analysis using LM labelled with a fluorescent probe, 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethylindocarbocyanine perchlorate (DiI). The absolute uptake of DiI(LM) by BCECs, measured by HPLC, was, however, almost 1/10 that of [3H]clinprost(LM), results which suggest the superiority of simple diffusion of clinprost over endocytosis of its LM form in the uptake of clinprost(LM) by BCECs. In the capillary‐depletion study with rat‐brain‐perfused [3H]clinprost(LM) from the internal carotid artery, the parenchyma apparent distribution volume was about 45 times larger than that of the capillary, showing that [3H]clinprost(LM) was transported through the blood‐brain barrier into the brain. The permeability coefficients of [3H]clinprost and [3H]clinprost(LM) determined by in‐situ brain perfusion in normal rats were considerably higher than those of the active metabolite [3H]isocarbacyclin and its LM form. In addition, the Blood‐brain‐barrier permeabilities to [3H]clinprost, [3H]isocarbacyclin and their LM forms in ischaemic rats were almost identical to those in normal rats. It was concluded that clinprost(LM) was transported through the blood‐brain barrier by endocytosis of LM, simple diffusion of clinprost released from LM, and transport of isocarbacyclin generated by hydrolysis of clinprost. The blood‐brain‐barrier permeability of clinprost(LM) is not reduced in ischaemic conditions, because the simple diffusion of clinprost released from LM contributed mainly to clinprost(LM) transport.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier</subject><subject>Brain Ischemia - metabolism</subject><subject>Cattle</subject><subject>Cells, Cultured</subject><subject>Drug Carriers</subject><subject>Epoprostenol - administration &amp; dosage</subject><subject>Epoprostenol - analogs &amp; derivatives</subject><subject>Epoprostenol - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Lipids</subject><subject>Medical sciences</subject><subject>Microspheres</subject><subject>Permeability</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostaglandins, Synthetic - administration &amp; dosage</subject><subject>Prostaglandins, Synthetic - pharmacokinetics</subject><subject>Rats</subject><subject>Rats, Inbred F344</subject><issn>0022-3573</issn><issn>2042-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1v0zAYhS0EGmXwE5AshHZFguPPhKtt1b5Qu_WiiEvLcd4UlzTJ7FTr_j2OGvUe3_iVznmPjx-EvmQkzeL5vk0p4TRRmcjTrChkOpRE5AVLD2_Q7CS9RTNCKE2YUOw9-hDClhCipJRn6CwvBBOEzhBcN11XJaU3rk1K470Dj9fetKHv_IC7Gi9c7yq8dNZ3of8DHgKed-0Q_a7d4Hnj2j4qwzds8GoczKYxbeVa_EDxVWuabrOHj-hdbZoAn6b7HP26vVnP75PF093D_GqRWE4ES4ARMCBqZUtBQZW2hFoKaXNqjMyBScYlzRWvjeDCZJXKbVFwzm1GhWTKsHN0ccyNlZ73EAa9c8FCExtBtw9a5ZJwTvJo_HE0jr8KHmrde7cz_lVnRI-M9VaPIPUIUo-M9cRYH-Ly5-mVfbmD6rQ6QY3610k3wZqmjjStCycb5WPnLNouj7YX18DrfxTQP1f3q3GMEckxwoUBDqcI4_9qqZgS-vfjnV5er2-Xslhoyv4BOOio-Q</recordid><startdate>199610</startdate><enddate>199610</enddate><creator>Minagawa, Toshiya</creator><creator>Sakanaka, Kohji</creator><creator>Inaba, Shin-Ichi</creator><creator>Sai, Yoshimichi</creator><creator>Tamai, Ikumi</creator><creator>Suwa, Toshio</creator><creator>Tsuji, Akira</creator><general>Blackwell Publishing Ltd</general><general>Pharmaceutical Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199610</creationdate><title>Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue</title><author>Minagawa, Toshiya ; Sakanaka, Kohji ; Inaba, Shin-Ichi ; Sai, Yoshimichi ; Tamai, Ikumi ; Suwa, Toshio ; Tsuji, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4053-e30eae5f7cb52e7bcbef656c82aa68e363462874fa545a1d78c99444c125637a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier</topic><topic>Brain Ischemia - metabolism</topic><topic>Cattle</topic><topic>Cells, Cultured</topic><topic>Drug Carriers</topic><topic>Epoprostenol - administration &amp; dosage</topic><topic>Epoprostenol - analogs &amp; derivatives</topic><topic>Epoprostenol - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Lipids</topic><topic>Medical sciences</topic><topic>Microspheres</topic><topic>Permeability</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostaglandins, Synthetic - administration &amp; dosage</topic><topic>Prostaglandins, Synthetic - pharmacokinetics</topic><topic>Rats</topic><topic>Rats, Inbred F344</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minagawa, Toshiya</creatorcontrib><creatorcontrib>Sakanaka, Kohji</creatorcontrib><creatorcontrib>Inaba, Shin-Ichi</creatorcontrib><creatorcontrib>Sai, Yoshimichi</creatorcontrib><creatorcontrib>Tamai, Ikumi</creatorcontrib><creatorcontrib>Suwa, Toshio</creatorcontrib><creatorcontrib>Tsuji, Akira</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minagawa, Toshiya</au><au>Sakanaka, Kohji</au><au>Inaba, Shin-Ichi</au><au>Sai, Yoshimichi</au><au>Tamai, Ikumi</au><au>Suwa, Toshio</au><au>Tsuji, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue</atitle><jtitle>Journal of pharmacy and pharmacology</jtitle><addtitle>J Pharm Pharmacol</addtitle><date>1996-10</date><risdate>1996</risdate><volume>48</volume><issue>10</issue><spage>1016</spage><epage>1022</epage><pages>1016-1022</pages><issn>0022-3573</issn><eissn>2042-7158</eissn><coden>JPPMAB</coden><abstract>Because the permeability of the blood‐brain barrier to lipid microspheres (LMs) has not hitherto been demonstrated, blood‐brain‐barrier permeability to LM containing the prostaglandin I2 analogue clinprost has been evaluated for an in‐vitro system of primary cultured monolayers of bovine brain capillary endothelial cells (BCECs), by a capillary depletion study in rats and by an in‐situ brain perfusion study in normal and 4‐vessel‐occluded fore brain ischaemic rats. Although energy‐dependency was not observed in [3H]clinprost uptake by BCECs, in accordance with results for simple diffusional transport, uptake of [3H]clinprost contained in lipid microspheres (denoted [3H]clinprost(LM)) was significantly inhibited by the endocytosis inhibitor, dansylcadaverine. The transport of LM into BCECs by endocytosis was also confirmed by fluorescence microscopy and flow‐cytometric analysis using LM labelled with a fluorescent probe, 1,1′‐dioctadecyl‐3,3,3′,3′‐tetramethylindocarbocyanine perchlorate (DiI). The absolute uptake of DiI(LM) by BCECs, measured by HPLC, was, however, almost 1/10 that of [3H]clinprost(LM), results which suggest the superiority of simple diffusion of clinprost over endocytosis of its LM form in the uptake of clinprost(LM) by BCECs. In the capillary‐depletion study with rat‐brain‐perfused [3H]clinprost(LM) from the internal carotid artery, the parenchyma apparent distribution volume was about 45 times larger than that of the capillary, showing that [3H]clinprost(LM) was transported through the blood‐brain barrier into the brain. The permeability coefficients of [3H]clinprost and [3H]clinprost(LM) determined by in‐situ brain perfusion in normal rats were considerably higher than those of the active metabolite [3H]isocarbacyclin and its LM form. In addition, the Blood‐brain‐barrier permeabilities to [3H]clinprost, [3H]isocarbacyclin and their LM forms in ischaemic rats were almost identical to those in normal rats. It was concluded that clinprost(LM) was transported through the blood‐brain barrier by endocytosis of LM, simple diffusion of clinprost released from LM, and transport of isocarbacyclin generated by hydrolysis of clinprost. The blood‐brain‐barrier permeability of clinprost(LM) is not reduced in ischaemic conditions, because the simple diffusion of clinprost released from LM contributed mainly to clinprost(LM) transport.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8953502</pmid><doi>10.1111/j.2042-7158.1996.tb05893.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3573
ispartof Journal of pharmacy and pharmacology, 1996-10, Vol.48 (10), p.1016-1022
issn 0022-3573
2042-7158
language eng
recordid cdi_proquest_miscellaneous_78604408
source Oxford University Press Journals All Titles (1996-Current); MEDLINE
subjects Animals
Biological and medical sciences
Blood-Brain Barrier
Brain Ischemia - metabolism
Cattle
Cells, Cultured
Drug Carriers
Epoprostenol - administration & dosage
Epoprostenol - analogs & derivatives
Epoprostenol - pharmacokinetics
General pharmacology
Lipids
Medical sciences
Microspheres
Permeability
Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions
Pharmacology. Drug treatments
Prostaglandins, Synthetic - administration & dosage
Prostaglandins, Synthetic - pharmacokinetics
Rats
Rats, Inbred F344
title Blood-brain-barrier Transport of Lipid Microspheres Containing Clinprost, a Prostaglandin I2 Analogue
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T15%3A39%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood-brain-barrier%20Transport%20of%20Lipid%20Microspheres%20Containing%20Clinprost,%20a%20Prostaglandin%20I2%20Analogue&rft.jtitle=Journal%20of%20pharmacy%20and%20pharmacology&rft.au=Minagawa,%20Toshiya&rft.date=1996-10&rft.volume=48&rft.issue=10&rft.spage=1016&rft.epage=1022&rft.pages=1016-1022&rft.issn=0022-3573&rft.eissn=2042-7158&rft.coden=JPPMAB&rft_id=info:doi/10.1111/j.2042-7158.1996.tb05893.x&rft_dat=%3Cproquest_cross%3E78604408%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78604408&rft_id=info:pmid/8953502&rfr_iscdi=true